TLR1/2 Specific Small‐Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes

Toll‐like receptor 2 (TLR2) expressed on antigen presenting cells evokes a series of critical cytokines, which favor the development of tumor‐specific cytotoxic T lymphocytes (CTLs). Therefore, TLR2 represents an attractive cancer immunotherapeutic target. Here, a synthetic library of 14 000 compoun...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Adv Sci (Weinh)
Auteurs principaux: Cen, Xiaohong, Zhu, Gengzhen, Yang, Junjie, Yang, Jianjun, Guo, Jiayin, Jin, Jiabing, Nandakumar, Kutty Selva, Yang, Wei, Yin, Hang, Liu, Shuwen, Cheng, Kui
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Communications
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6523386/
https://ncbi.nlm.nih.gov/pubmed/31131189
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201802042
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires